Thyroid Hormones membrane receptor, Integrin αvβ3 as a potential prognostic marker of chemotherapy response in breast cancer

JOHANNA DIAZ ALBUJA; STERLE HA; CAYROL MF; PAULAZO MA; MATEO N CAMPOS HAEDO; DEBERNARDI MM; ROSEMBLIT C; CREMASCHI GA; DIAZ FLAQUE MC

Atlanta, Georgia

Congreso; Endocrine Society Annual Meeting; 2022

Endocrine Society

Thyroid Hormones membrane receptor, Integrin αvβ3 as a potential prognostic marker of chemotherapy response in breast cancer 1NEUROIMMUNOMODULATION AND MOLECULAR ONCOLOGY LABORATORY, INSTITUTE FOR BIOMEDICAL RESEARCH (BIOMED), SCHOOL OF MEDICAL SCIENCES, PONTIFICAL CATHOLIC UNIVERSITY OF ARGENTINA (UCA), AND THE NATIONAL SCIENTIFIC AND TECHNICAL RESEARCH COUNCIL (CONICET), BUENOS AIRES, ARGENTINADiaz Albuja J.A.1, Sterle H.A.1, Cayrol F.1, Paulazo M.A.1, Campos Haedo M.1, Debernardi M.1, Rosemblit C.1 Graciela A Cremaschi1, Díaz Flaqué M.C.1Despite the development of novel therapies, breast cancer (BC) tumors are treated with conventional therapy sooner or later. Due to tumor heterogeneity, it is necessary to define new biomarkers to identify groups with different molecular characteristic to improve the correct treatment decision. The impact of thyroid status in BC growth has previously been studied. In particular, it has been found alterations of thyroid function during chemotherapy BC treatment and demonstrated that T3 induces chemosensitization of BC cells. However, the relationship between thyroid hormones (THs) membrane receptor, integrin αvβ3 and BC response to chemotherapy remains unclear. The aim of this study is to evaluate the relationship between THs and integrin αvβ3 expression as prognostic value in BC patients.The mRNA expression of ITGB3 in TCGA-PanCancer Atlas, BC dataset (1084 patients) were associated with worse overall survival. Moreover, ITGB3 mRNA expression was significantly correlated with genes encoding multidrug resistance protein transporters MDR1 and BCRP such as ABCB1 and ABCG2, (Pearson, R score >0.3 and p